What's next in tech
Shares of Aryx Therapeutics, the Fremont biopharmaceutical, got bombed Wednesday following news released late the day before that its latest clinical trial of tecafarin, its novel blood-clot treatment, failed to achieve Read More → 
Aryx Therapeutics, the the Fremont biopharmaceutical whose shares were slammed last July when Procter & Gamble pulled out of a partnership in developing Aryx’s drug to treat chronic constipation and abdominal Read More → 
Aryx Therapeutics, the Fremont biopharamaceutical whose shares were slammed last July when Procter & Gamble pulled out of a partnership in developing Aryx's drug to treat chronic constipation Read More → 
Aryx Therapeutics "regretfully announced'' Monday that it wouldn't be able to make a presentation as previously planned at a healthcare conference Wednesday put together by New York Read More → 
